News >

Next Steps in Bladder Cancer Include Chemoimmunotherapy, Targeted Agents, and ADCs

Gina Columbus @ginacolumbusonc
Published: Thursday, May 09, 2019

Guru Sonpavde, MD

Guru Sonpavde, MD
While there are 5 single-agent checkpoint inhibitors approved for the second-line treatment of patients with metastatic urothelial cancer, and 2 in the frontline space, ongoing studies of combining immunotherapy with chemotherapy have the potential to further improve patient outcomes, explained Guru Sonpavde, MD.

For example, the phase III KEYNOTE-361 study (NCT02853305) is evaluating the efficacy and safety of pembrolizumab (Keytruda) with or without chemotherapy compared with chemotherapy alone in patients with advanced or metastatic urothelial carcinoma.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication